Equities

Phathom Pharmaceuticals Inc

PHAT:NSQ

Phathom Pharmaceuticals Inc

Actions
  • Price (USD)18.72
  • Today's Change-0.51 / -2.65%
  • Shares traded1.36m
  • 1 Year change+68.95%
  • Beta0.6895
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments381155183
Total Receivables, Net1.64----
Total Inventory1.21----
Prepaid expenses135.133.27
Other current assets, total------
Total current assets397161187
Property, plant & equipment, net3.623.492.56
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets9.930.300.34
Total assets414165189
LIABILITIES
Accounts payable1310.005.15
Accrued expenses191614
Notes payable/short-term debt000
Current portion long-term debt/capital leases7.11--0
Other current liabilities, total------
Total current liabilities392619
Total long term debt43820590
Total debt44520590
Deferred income tax------
Minority interest------
Other liabilities, total108.608.68
Total liabilities487240117
SHAREHOLDERS EQUITY
Common stock0.010.000.00
Additional paid-in capital856652602
Retained earnings (accumulated deficit)(929)(727)(529)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity(73)(75)72
Total liabilities & shareholders' equity414165189
Total common shares outstanding584231
Treasury shares - common primary issue0.020.021.14
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.